
About BGI
BGI is a publicly listed company based in Shenzhen (China) founded in 1999. BGI is engaged in genomics and precision medicine solutions. It operates on a HealthTech and Professional Services model. The company has 3,700 employees. Its chief executive, as recorded, is Wang Jian. Its website bgi.com draws about 152 thousand monthly visits. BGI offers products and services including NIFTY®200+, Liver and Pancreatic Tumor Testing, and Rare Disease Genomic Diagnosis. Its focus areas include Biotechnology and Genomics. Its legal entity is Shenzhen BGI Genomics Co., Ltd. Its competitors include Novogene Corporation and Beikang Medical; 2 of its 2 listed competitors have raised funding.
Company details
BGI, based in Shenzhen, China, is focused on advancing life sciences through genomics and precision medicine. The company is involved in genetic testing, oncology solutions, and rare disease diagnosis. Services are provided across maternal and child health, tumor prevention, infectious disease control, and chronic disease management. Operations span multiple regions in China, integrating clinical, research, and public health initiatives to enhance healthcare outcomes. BGI is committed to reducing birth defects and improving global health standards through innovative technologies.
- Annual Revenue$528.49 M (USD)-4.21as on Dec 31, 2025
- Net Profit-$88.08 M (USD)31.69as on Dec 31, 2025
- EBITDA$734.18 K (USD)as on Dec 31, 2025
- Latest Funding Round$300M (USD), Post-IPO
Feb 2021
- InvestorsSDIC
& 1 more
- Employee Count3,700
Products & Services of BGI
BGI offers a comprehensive portfolio of products and services, including NIFTY®200+, Liver and Pancreatic Tumor Testing, and Rare Disease Genomic Diagnosis.
Non-invasive prenatal testing for single-gene disorders offered.
Genetic testing for late-stage tumor survival solutions.
Genomic solutions for rare disease diagnosis provided.
Funding Insights of BGI
- Total Rounds 2
- Last Round Post-IPO — $300M
- First Round $350,669
(Jan 2015)
- Investors Count 2
All 2 funding rounds of BGI with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2021 | $300M | Post-IPO | – | – | |
| Jan 2015 | $350,669 | Grant | – | – |
2 investors in total: 2 institutional.
Investors in BGI
BGI has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include SDIC and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investment holding company | 1995 | sdic.com.cn | Beijing, China | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for BGI
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of BGI
50 people are tracked at BGI (8 in leadership, 14 in board & advisors, 28 in team); the tracked headcount is 3,700.
| Name | Role | Group |
|---|---|---|
Wang Jian | Chairman & CEO | Leadership |
Yin Ye | General Manager | Leadership |
Ray Wong | Domestic BD Director For Medicalbigdata Reasearch At BGI Group | Leadership |
Mark Sun | HR Director | Leadership |
Hongyan An | Director Of Sale/business Unit Head | Leadership |
Hang Su | HR Business Partner | Leadership |
Chao Jia | Internet Product Director | Leadership |
Jessica Wang | Chief Product Director | Leadership |
Wu Chun | Board Member | Board & advisors |
Li Songgang | Supervisory Board Chairman | Board & advisors |
Chen Penghui | Board Member | Board & advisors |
Xu Aimin | Independent Board Member | Board & advisors |
Guo Jinlong | Independent Board Member | Board & advisors |
Jiang Changjian | Independent Board Member | Board & advisors |
Li Yingrui | Board Member | Board & advisors |
Zhao Qian | Board Member | Board & advisors |
Wang Hongtao | Board Member | Board & advisors |
Sun Yingjun | Board Member | Board & advisors |
Xie Hong | Independent Board Member | Board & advisors |
Jin Chunbao | Board Member | Board & advisors |
30 more people are available in the full profile.
Complete people profiles for BGI
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of BGI
BGI is a publicly listed company on the SZSE with ticker symbol 300676 in China, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date14 Jul 2017
- Listed onSZSE: 300676
- Listed entityBGI Genomics Co. Ltd. Class A
- Exchange sectorHealth technology
- ISINCNE100003449
- Share price42.34 CNY (-1.42% on the day) · 2026-10-14
- Market capitalisation17,794,916,179.00 CNY
- EPS (diluted, trailing year)-1.38 CNY
- Volume (last session)7,502,042
Financials of BGI
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 3.70B CNY | -616.7M CNY | 5.1M CNY |
| 2024 | 3.86B CNY | -902.7M CNY | -132.1M CNY |
| 2023 | 4.34B CNY | 92.9M CNY | 582.6M CNY |
| 2022 | 7.05B CNY | 802.8M CNY | 1.22B CNY |
| 2021 | 6.75B CNY | 1.46B CNY | 2.02B CNY |
Detailed financial statements for BGI
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of BGI
4 dated milestones of BGI across 22 years, from founding to its latest funding, stage changes and deals.
- Founded BGI is founded.
- Funding First funding round of $351K.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $300.0M.
Competitors of BGI
BGI has 2 listed competitors in our database, 2 of them funded. They include Novogene Corporation and Beikang Medical.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| novogene.com | 2011 | Beijing, China | $75M | 141 | Genomic services and solutions with NGS expertise are provided. | |
| basecare.cn | 2010 | Suzhou, China | $36.52M | NGS-based diagnostic solutions for neonatal screening are developed. |
Detailed competitors of BGI
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of BGI
The website of BGI (bgi.com) receives about 152.2K visits a month.
- Monthly visits152.2K
▲ 52.9% vs previous month
Websites whose visitors overlap most with BGI. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| genomics.cn | 100% | 257.6K | #132,136 | View details | |
cd-genomics.com | cd-genomics.com | 80% | #300,823 | – | |
cloud.majorbio.com | cloud.majorbio.com | 78% | – | ||
| yeasen.com | 71% | 69K | #449,589 | View details | |
| rna-seqblog.com | 71% | #669,184 | View details | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 15 similar websites and full traffic analytics for BGI
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 15 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Bgi
Complete news archive for BGI
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BGI
BGI was founded in 1999 and raised its 1st funding round 16 years after it was founded.
BGI is headquartered in Shenzhen, China. It is registered at Shenzhen, Guangdong, China.
Wang Jian is the CEO of BGI, as recorded in our data.
BGI has 3,700 employees.
Annual revenue of BGI is $528.49M as on Dec 31, 2025.
BGI, based in Shenzhen, China, is focused on advancing life sciences through genomics and precision medicine. The company is involved in genetic testing, oncology solutions, and rare disease diagnosis. Services are provided across maternal and child health, tumor prevention, infectious disease control, and chronic disease management. Operations span multiple regions in China, integrating clinical, research, and public health initiatives to enhance healthcare outcomes. BGI is committed to reducing birth defects and improving global health standards through innovative technologies.
BGI's top competitors include Novogene Corporation and Beikang Medical.
BGI offers NIFTY®200+, Liver and Pancreatic Tumor Testing, and Rare Disease Genomic Diagnosis.
Yes, BGI is publicly traded on SZSE under the ticker symbol 300676.
BGI has 2 investors. Key investors include SDIC, and European Union.
BGI operates through Shenzhen Bgi Genomics Co., Ltd..
The website of BGI receives about 152 thousand visits a month.
